AI Market Mood: Stock Dashboard
PAX
Fundamental
Technical:
Latest News:
Pfizer denies offering Seoul double Paxlovid's supply price < Pharma < Article - KBR neutral
PFE
Summary: Pfizer Korea denied reports of requesting to double the supply price of its Covid-19 drug Paxlovid, ensuring ongoing discussions and cooperation with the government.
Full articlePfizer Will Charge $1,390 For 1 Course Of COVID Drug Paxlovid On Commercial Market somewhat bearish
PFE
Summary: Pfizer plans to price a course of the oral antiviral COVID-19 treatment Paxlovid at $1,390, significantly higher than what the government has paid, but various programs will assist with costs. Pfizer's sales forecast for the year has been reduced due to a drop in Paxlovid prescriptions and vaccine sales.
Full articleUPDATE 4-Pfizer's COVID antiviral Paxlovid gains full US approval - Yahoo Sport Australia somewhat bullish
PFE
Summary: The U.S. FDA granted full approval to Pfizer's oral antiviral COVID-19 treatment Paxlovid, clearing the way for commercial sales at market rates, Pfizer sold around $18.9 billion of Paxlovid last year and forecasts sales of about $8 billion for 2023, ICER recommended a price range of $563 to $906 per treatment course for Paxlovid.
Full articleAre Americans losing their taste for Starbucks? - KPAX somewhat bearish
SBUX
Summary: Starbucks faces dwindling sales and consumer disengagement due to the pandemic, competition from independent cafes, and labor disputes, prompting a decline in its quarterly revenue for the first time since 2020.
Full articleBank of America Securities Reaffirms Their Hold Rating on Patria Investments (PAX) neutral
PAX
Summary: Bank of America Securities analyst Craig Siegenthaler maintained a Hold rating on Patria Investments, PAX shares opened at $12.98. The Street indicates a Hold analyst consensus rating for Patria Investments.
Full articleEPIC-SR: The negative paxlovid data Pfizer has been sitting on - First10EM somewhat bearish
PFE
Summary: EPIC-SR study reveals no benefit from paxlovid in treating COVID-19 patients, leading to the conclusion of not prescribing paxlovid in the vast majority of patients. The negative data from EPIC-SR contradicts Pfizer's rushed positive EPIC-HR study.
Full article